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Background: Faecal immunochemical tests (FITs) are commonly used in colorectal cancer (CRC) screening. Diagnostic
accuracy of FIT differs between males and females. This so far unexplained difference could result in a dissimilarity in
screening outcome between both sexes. The aim of this study is to compare sensitivity and specificity of a FIT
between males and females, and study potential explanatory variables.
Methods: In this cross-sectional study, data were prospectively collected. 3,022 subjects performed a FIT prior to
complete colonoscopy. Sensitivity, specificity, and ROC curves were compared for both sexes. Potential explanatory
variables of the relation between sensitivity and sex were explored.
Results: At all cut-off values, FIT sensitivity for CRC was higher (range 13-23%) and specificity was lower (range 2-4%) in
males compared to females. At 75 ng/ml, sensitivity for CRC was 93% in males compared to 71% in females (p = 0.03),
and specificity was 90% in males compared to 93% in females (p = <0.05). For advanced adenomas, males had a
slightly higher sensitivity and lower specificity (not significant). At 75 ng/ml, sensitivity for advanced adenomas
was 33% in males compared to 29% in females (p = 0.46), and specificity was 93% in males compared to 95% in
females (p = 0.22). ROC curves were similar for both sexes, and equal combinations of sensitivity and specificity
could be achieved by adjusting the cut-off values. For CRC, the difference in sensitivity could not be explained by
age or location of the tumour.
Conclusions: FIT has a higher sensitivity and a lower specificity for CRC in males than in females. Equal test
characteristics can be achieved by allowing separate cut-off values for both sexes. Location and age do not explain the
observed differences in sensitivity.
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Colorectal cancer (CRC) is a leading cause of cancer re-
lated death worldwide [1]. Early detection by population
screening is the most realistic approach to reduce CRC-
related death. Faecal immunochemical tests (FITs) are in-
creasingly used as the primary screening test for CRC [2].* Correspondence: s.vanturenhout@vumc.nl
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article, unless otherwise stated.Recently, it was found that FITs have a higher sensitivity
and lower specificity for advanced colorectal neoplasia in
males compared to females [3]. Although diagnostic
accuracy of a screening test is just one of several factors
determining the efficiency of a screening programme, a
difference in FIT characteristics between males and
females could implicate disparities in the expected benefit
from CRC screening. Such a difference may require
tailored screening. Whether this difference reflects, for
example, a dissimilarity in advanced neoplasia distribution
or a difference in the age of onset of CRC, remains to be
resolved.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
van Turenhout et al. BMC Gastroenterology  (2014) 14:217 Page 2 of 10The aim of the present study is to investigate whether
the sensitivity and specificity of a frequently used FIT for
the detection of CRC and advanced adenomas differs be-
tween males and females, and whether this difference




For the current analysis, data were used from an on-
going study programme on FIT performance. This
programme aims to answer several research questions
and has been previously described extensively [4-6]. In
short, individuals scheduled for elective colonoscopy in
5 participating medical centres were invited to participate
and perform a FIT prior to colonoscopy. In addition to
the exclusion criteria of these previous studies, individuals
with an indication of visible rectal bleeding or anaemia
were excluded from the analysis to minimize potential work-
up bias. Use of NSAIDs and/or aspirin was no exclusion
criterium, and subjects were not advised on whether to con-
tinue this medication on the day of colonoscopy. The study
was approved by the VU University Medical Centre Ethics
Committee, Kennemergasthuis Ethics Committee, Sint
Lucas Andreas Ethics Committee, Zaans Medical Centre
Ethics Committee and Slotervaart Hospital Ethics Commit-
tee. All participants provided written informed consent.
Study design
In this cross-sectional study, data were collected pro-
spectively. The test used was an automated FIT with
quantitative results: OC-sensor® (Eiken Chemical Co.,
Tokyo, Japan). One experienced technician performed
the analyses, and was kept unaware of the clinical data.
All tests were analysed by using the OC sensor MICRO
desktop analyser (Eiken Chemical co, Tokyo, Japan) [7]. A
cut-off of ≥75 ng/ml is advised by the manufacturer. Here,
haemoglobin concentrations of ≥50, ≥75, ≥100, and
≥200 ng/ml of buffer solution were taken as cut-off values.
These concentrations correspond to faecal haemoglobin
concentrations of respectively ≥10, ≥15, ≥20 and ≥40
milligram of haemoglobin per gram of faeces.
Colonoscopy and lesions
Experienced gastroenterologists performed or supervised
all colonoscopies. The endoscopists were unaware of the
FIT result, in order to prevent investigator bias. Con-
scious sedation by midazolam was offered to all patients.
A colonoscopy was considered complete when the cae-
cum was intubated with identification of the appendicle
orifice and valvula Bauhini, or when an obstructing neo-
plasm was found. Quality control measures included
documentation of colonic landmarks. Individuals in whom
the bowel cleansing was insufficient, and individuals inwhom the colonoscopy remained incomplete were ex-
cluded from analysis. However, if a barium enema, virtual
colonography or second colonoscopy was performed
within six months, evaluation of the colon was considered
complete and the subject was included in analysis. The
right colon was defined as the proximal part of the colon
including caecum, ascending colon, right (or hepatic) flex-
ure and transverse colon. The left colon was defined as
the distal part of the colon including left (or splenic) flex-
ure, descending colon, sigmoid and rectum [8,9]. In case
of multiple neoplasia detected on colonoscopy, patients
were classified based on the most advanced lesion found.
Tissue samples obtained at colonoscopy were sent to
the department of pathology and evaluated according to
current standards. Adenomas ≥1.0 cm, adenomas with a
villous component (i.e. tubulovillous or villous adenoma)
or adenomas with severe/high-grade dysplasia were clas-
sified as advanced adenomas [10,11].
Statistical analysis
Using colonoscopy as the reference test, sensitivities and
specificities of FIT were calculated for two definitions of
colonoscopy outcome: (i) the presence of CRC and (ii)
the presence of advanced adenoma. Sensitivity was de-
fined as the proportion of positive test results in patients
with the colonoscopy outcome under consideration. Spe-
cificity was calculated as the proportion of negative test
results in patients with an outcome less severe than the
outcome under consideration.
Sensitivity and specificity of FIT at different cut-off
values were compared between males and females using
the Fisher Exact test. Analyses were repeated for the
symptomatic and screening/surveillance indication groups
separately. Receiver Operating Characteristic (ROC)
curves were plotted for both sexes separately and the
Areas Under the ROC Curves (AUC’s) were calculated,
along with their 95% confidence intervals. The 95%
confidence intervals were used to compare diagnostic
capabilities.
To study whether sex dissimilarities are a reflection of
differences in age, location and size or number of neoplas-
tic lesions, a stratified analysis of 2×2 contingency tables
was performed, with statistical testing using the Fishers
Exact test. Age was dichotomized into subjects <65 and
65 or older. Location was divided in left and right sided le-
sions. The number of advanced adenomas was grouped as
1 or >1, and size was grouped <10 mm or ≥10 mm.
In addition, the effect of these covariates on the rela-
tion between test sensitivity (for CRC and advanced ad-
enoma) and sex was studied in a multivariate logistic
regression analysis. In this analysis, we aimed to estimate
the independent effect of each factor after adjusting for
the contributions of other variables in the model. Full
multivariate models (i.e., forced entry with no variable
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the extent to which the coefficient of sex would be influ-
enced when including other covariates in the model.
The Wald test was used to detect significant factors in
multivariate logistic regression analysis models. Age was
used as continuous variable. To avoid dilution of the po-
tential independent effect of location on FIT results,
subjects with CRC on both sides of the colon, and sub-
jects with advanced adenomas on both sides of the colon
were excluded from the multivariate analysis. Stratified
analyses and the multivariate analysis were performed
for a FIT cut-off value of 50, 75 and 100 ng/ml. The
manuscript contains the results at the cut-off value of
75 ng/ml. In the supplementary data, the results of
multivariate logistic regression analysis for CRC and
advanced adenomas are shown for the cut-off values of
50 and 100 ng/ml. The variables studied for CRC and
advanced adenomas were sex, age, and location of the
lesion. Additionally, T-stage and presence of advanced
adenomas were used as variables for predicting sensitiv-
ity for CRC. For advanced adenomas, the size and num-
ber of advanced adenomas were added to the analysis.
There was no correction of p-values to recognize that
several tests of statistical significance were performed on
data arising from individual patients, because the purpose
of the research was to highlight any potential differences.
All analyses were performed with SPSS for Windows
Version 20 (SPSS Inc., Chicago, USA).
Results
Participants
Between June 2006 and October 2010, 4,704 subjects
returned a FIT and underwent colonoscopy. Of these,
1,682 were excluded for different reasons (see Figure 1),
leaving 3,022 participants for analysis. As the first colonos-
copy was incomplete in 107 participants, a second colon-
oscopy, barium enema or CT-colonography was needed to
complete the colonoscopic evaluation. The mean age of
the participants was 59.7 years (range 19–91 years, SD
12.6), and 45% was male. The indication for colonoscopy
was evaluation of symptoms in 44% (1,331/3,022), screen-
ing or surveillance in 47% (1,412/3,022), and unspecified
in 9% (279/3,022) (see Table 1). Characteristics of included
males and females are shown in Table 2.
Colonoscopy
In 2.3% of the included subjects, CRC was found (69/3,022)
and in another 10.1% one or more advanced adenomas
were detected (304/3,022; see Figure 1). From all subjects
with CRC, 11.6% (8/69) also had one or more advanced
adenomas. Males were found to have a higher prevalence
of CRC (45/1357 = 3.3%) than females (24/1665 = 1.4%;
p = 0.001). The distribution of CRC stages according to the
TNM classification, is demonstrated in Figure 1. TheT-stage (Tumour-stage) distribution was 16% (11/69) T1,
25% (17/69) T2, 33% (23/69) T3 and 6% (4/69) T4. In 14
(20%) individuals with CRC, T-stage was unknown due to
preoperative radiotherapy, or was not determined because
of disseminated disease at time of diagnosis. The prevalence
of T1/T2 and T3/T4 tumours was comparable in males
(17/32 = 53%) and females (11/23 = 48%; p = 0.70).
Positivity rates
For the total population, the FIT positivity rate was
12.3% and 12.7% at a cut-off level of 50 and 75 ng/ml,
respectively. The positivity rate decreased with increas-
ing cut-off values, to 6.8% at 200 ng/ml. Males were
found to have a higher positivity rate (50 ng/ml; 15.3%,
75 ng/ml; 12.7%) compared to females (50 ng/ml; 9.8%,
75 ng/ml; 8.3%, p-values < 0.001).
Sensitivity and specificity
In the total study population, the sensitivity for CRC at a
cut-off value of 50 and 75 ng/ml was 88% and 86%,
respectively. Specificity was 90% and 92% at 50 and 75
ng/ml. For advanced adenomas, sensitivity and specificity
were 35% and 92% at 50 ng/ml and 31% and 94% at
75 ng/ml, respectively (see Table 3). At all cut-off values,
males were found to have a higher sensitivity for CRC
than females. The difference in sensitivity ranged from
13% to 23% and was largest and significant at the cut-offs
75 and 100 ng/ml. More specifically, at 75 ng/ml, sensitiv-
ity for CRC was 93% in males compared to 71% in females
(p = 0.03). The specificity for CRC was significantly lower
in males compared to females, but the difference was
small (between 2.2 and 3.9%, see Table 3). For advanced
adenomas, the differences in sensitivity and specificity be-
tween males and females showed the same pattern as for
CRC. However, the higher sensitivity in males was small
(not significant, see Table 3). Only specificity of FIT in
males at a cut-off value of 50 ng/ml was significantly lower
than in female participants (see Table 3).
Results for the symptomatic and screening/surveillance
indication groups separately are in line with results for the
total population. In the group with symptomatic indivi-
duals, sensitivity for CRC at 75 ng/ml was 93% in males
and 81% in females. In the screening/surveillance group
these figures were 100% and 50% respectively. However, the
screening/surveillance group consisted of only 14 carci-
nomas. The specificity for CRC at 75 ng/ml in the symp-
tomatic group was in 92% males and 92% in females. In the
screening/surveillance group these figures were 90% and
93% respectively. For advanced adenomas, sensitivity at
75 ng/ml in the symptomatic group was 26% in males and
in 32% females. These figures were respectively 33% and
24% in the screening/surveillance group. In the symptom-
atic group, specificity for advanced adenomas at 75 ng/ml
was 94% in males and also 94% in females. For the
Figure 1 Study flow diagram. 1Incomplete colon evaluation in spite of possible additional evaluation by repeated colonoscopy, barium enema
or virtual colonography within 6 months. 2CRC stage remained unsure as these cases received pre-operative radiotherapy or due to disseminated
disease exact classification remained unknown.
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95% respectively.
Receiver operating characteristic curves
The test characteristics for males and females at each
cut-off value are visualized in the ROC curves in
Figures 2 and 3. The AUC’s for CRC for males and fe-
males were 0.95 (95% CI 0.909-0.985) and 0.90 (95% CI0.819-0.981) respectively. The ROC curves and AUC’s
for advanced adenoma were very similar between males
and females (see Figure 3).The influence of potential explanatory variables
In patients with CRC, males were found to have a higher
FIT positivity rate than females (50 ng/ml 93% vs. 79%,
Table 1 Primary indication for colonoscopy among 3,022
consecutive patients included for analysis of FIT
characteristics according to sex
Indication group Indication for colonoscopy N
Symptomatic Weight loss 88
Clinical suspicion of diverticulitis 26
Clinical suspicion of IBD 40
Abdominal pain 355
Altered bowel habits 548






Screening & surveillance Average risk 103
Familial history of CRC 482
Lynch syndrome 54
Polyp surveillance 578
Post CRC surveillance 195
Total 1,412
Other Not specified/others 279
Grand total 3,022
*This group includes individuals who were referred for colonoscopy as CRC was
suspected on abdominal sonography, CT/MRI scan or physical examination.
FIT = faecal immunochemical test, IBD = inflammatory bowel disease,
CRC = colorectal cancer.
Table 2 Characteristics of males and females with CRC
and advanced adenomas included in comparative
analysis of a FIT test
Males Females
Total number of subjects 1,312 1,641
CRC N = 45 N = 24
Mean age 68.0 years 68.8 years







Advanced Adenoma N = 164 N = 140
Mean age 63.9 years 64.3 years













*Cut-off value 75 ng/ml. CRC = colorectal cancer; FIT = faecal immunochemical test.
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by location (100% vs. 88% (left-sided) and 79% vs. 51%
(right-sided)). Overall for males and females, left sided
CRC was found to have a higher positivity rate (96%)
than right sided CRC (71%, p < 0.05). However, within
males and females with CRC, an equal proportion of
cancers was left sided. In multivariate analysis, location
and sex were found to be associated with FIT sensitivity
for CRC (see Table 4 and Additional file 1: Tables S1
and S2 for cut-off values 50 and 100 ng/ml). The univar-
iate odds ratio for sex (OR 5.8, 95% CI 1.3-25.0) was
only mildly affected by the inclusion of location and age
in the analysis (OR 6.2, 95% CI 1.2-32.9). As such, the
relation between sex and FIT sensitivity is not a result of
differences in age of the patients or location of the
tumour between males and females.
In individuals with advanced adenomas, males were
found to have a slightly higher positivity rate than females
(37% vs. 33%, n.s.). Left sided advanced adenomas were
more frequently positive (38%) than right sided lesions
(24%, p = 0.02). Also, subjects with more than one
advanced adenoma were found to have a higher FIT posi-
tivity rate (63%) than subjects with one advanced adenoma
(27%, p < 0.001). The same was found for subjects with an
advanced adenoma >9 mm (45%) compared to advanced
adenomas <10 mm (12%, p < 0.001).
In males, a slightly higher proportion of advanced
adenomas was right-sided (40% in males versus 32% in
females) and was large in size (76% in males versus 71%
in females). In addition, in men multiple synchronous
advanced adenomas were more common (21% in males
versus 17% in females, not significant). The distribution
of these explanatory variables caused a shift in the OR
for sex from 1.2 in the univariate analysis to 1.0 in the
multivariate analysis, indicating that the small difference
in sensitivity between males and females can be
explained by differences in the size and number of ad-
vanced adenomas (see Table 4 and Additional file 1:
Tables S1 and S2). In conclusion, the size and the num-
ber of advanced adenomas were important predictors of
FIT positivity in advanced adenomas, but sex was not.Discussion
In the present study, sensitivity and specificity of a fre-
quently used FIT was assessed in males and females in a
large cohort of subjects referred for colonoscopy. FIT
was found to be more sensitive and less specific for CRC
in men than in women. The areas under the ROC curves
were similar for males and females. By using different
cut-off values for both sexes, a similar sensitivity can be
reached. The difference in sensitivity between the sexes
could not be explained by age or location of the lesion.
The sensitivity of FIT for advanced adenomas was
Table 3 Comparison of sensitivity and specificity of a FIT for detection of CRC and advanced adenomas in males and females at different cut-off values
CRC Advanced adenoma
Sensitivity Sensitivity
FIT cut-off Total N = 69* Males N = 45* Females N = 24* Difference p-value FIT cut-off Total N = 304† Males N = 164† Females N = 140† Difference p-value
50 ng/ml (CI) 88.4% (78–95) 93.3% (82–99) 79.2% (58–93) 14.1% 0.12 50 ng/ml (CI) 34.9% (30–41) 36.6% (39–45) 32.9% (25–41) 3.7% 0.55
75 ng/ml (CI) 85.5% (75–93) 93.3% (82–99) 70.8% (49–87) 22.5% 0.03 75 ng/ml (CI) 30.9% (26–37) 32.9% (26–41) 28.6% (21–37) 4.3% 0.46
100 ng/ml (CI) 85.5% (75–93) 93.3% (82–99) 70.8% (49–87) 22.5% 0.03 100 ng/ml (CI) 28.6% (24–34) 31.7% (25–39) 25.0% (18–33) 6.7% 0.21
200 ng/ml (CI) 75.4% (64–85) 80.0% (65–90) 66.7% (45–84) 13.3% 0.25 200 ng/ml (CI) 21.1% (17–26) 24.4% (18–32) 17.1% (11–24) 7.3% 0.16
Specificity Specificity
FIT cut-off Total N = 2,953# Males N = 1,312# Females N = 1,641# Difference p-value FIT cut-off Total N = 2,649‡ Males N = 1,148‡ Females N = 1,501‡ Difference p-value
50 ng/ml (CI) 89.5%(88–91) 87.3% (85–89) 91.2% (90–93) −3,9% <0,05 50 ng/ml (CI) 92.3% (91–93) 90.8% (89–92) 93.4% (92–95) −2.6% <0.05
75 ng/ml (CI) 91.5% (90–95) 90.1% (88–92) 92.6% (91–94) −2,5% <0,05 75 ng/ml (CI) 94.0% (93–95) 93.4% (92–95) 94.5% (93–96) −1.1% 0.22
100 ng/ml (CI) 92.6% (92–94) 91.2% (90–93) 93.7% (92–95) −2,5% <0,05 100 ng/ml (CI) 95.0% (94–96) 94.4% (93–96) 95.5% (94–97) −1.1% 0.24
200 ng/ml (CI) 94.8% (94–96) 93.6% (21–95) 95.8% (95–97) −2,2% <0,05 200 ng/ml (CI) 96.6% (96–97) 96.2% (95–97) 97.0% (96–98) −0.8% 0.28
*This concerns the total of subjects with CRC from which the sensitivity was calculated. #This concerns the total of subjects without CRC from which the specificity was calculated. †This concerns the total of subjects
with advanced adenoma from which the sensitivity was calculated. ‡This concerns the total of subjects without CRC and without advanced adenomas from which the specificity was calculated. FIT = faecal













Figure 2 Receiver operating characteristic curve of FIT for detection of CRC. ROC = receiver operating characteristic; FIT = faecal
immunochemical test; CRC = colorectal cancer; AUC = area under the curve.
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lated to size and the number of advanced adenomas.
In males, FIT was found to have 13-23% higher sensi-
tivity for CRC than in females. Previous studies already
found a difference in test performance for the detection
of advanced neoplasia in males and females [3]. In the
German study, positive and negative predictive values, as
well as sensitivity and specificity were calculated. How-
ever, due to the inclusion of only 14 cases of CRC, test
characteristics could not be calculated for CRC. The
current study not only included a higher number of ad-
vanced adenomas, it also evaluated the relation between
sex and FIT sensitivity for CRC, corrected for the location
of colonic lesions and age of the participant. TheseFigure 3 Receiver operating characteristic curve of FIT for detection
FIT = faecal immunochemical test; AUC = area under the curve.variables were chosen because it is known that CRC de-
velops earlier in lifetime in men then in women [12]. In
addition, it is also known that females have a higher preva-
lence of right sided CRC [13]. Finally, left sided neoplasia
have a higher likelihood to test positive on FIT [9,14]. A
potential explanation for this phenomenon, could be a dif-
ference in degradation of haemoglobin between left and
right sided lesions, or difference in shape and tendency to
bleed between proximal and distal lesions [14].
In the multivariate analysis, location and sex were sig-
nificantly associated with FIT sensitivity for CRC, but
the univariate odds ratio for sex was not substantially af-
fected by the inclusion of location and age in the ana-
lysis. By stratified analysis of 2×2 contingency tables, itof advanced adenoma. ROC = receiver operating characteristic
Table 4 Level of significance and odds ratio’s for different variables used in a multivariate logistic regression model predicting sensitivity of a FIT at cut-off of
75 ng/ml for detection of CRC and advanced adenomas
CRC Advanced adenoma
Univariate model Multivariate model Univariate model Multivariate model
Variable OR (95% CI) p-value OR (95% CI) p-value Variable OR (95% CI) p-value OR (95% CI) p-value
Sex (ref = female) (N = 69) 5.77 (1.33-24.95) 0.02 6.16 (1.15-32.92) 0.03 Sex (ref = female) (N = 304) 1.23 (0.75-2.00) 0.41 1.00 (0.57-1.75) 0.99
Age (continuous variable) (N = 69) 1.01 (0.94-1.08) 0.89 1.00 (0.92-1.08) 0.96 Age (continuous variable) (N = 304) 1.01 (0.98-1.03) 0.55 1.00 (0.98-1.03) 0.75
Location (ref = right-sided) (N = 68) 4.30 (1.07-17.35) 0.04 4.83 (0.95-24.8) 0.05 Location (ref = right-sdided (N = 303) 1.94 (1.26-2.98) 0.002 1.31 (0.79-2.20) 0.30
T-stage (ref = T1) (N = 55) 1.57 (0.39-6.32) 0.53 2.19 (0.44-10.80) 0.34 AA size (ref = <10 mm) (N = 285) 5.58 (2.55-12.22) <0.001 5.24 (2.32-11.83) <0.001
Presence of AA (ref = none) (N = 69) 0.83(0.09-7.54) 0.87 1.38 (0.09-20.52) 0.81 Number of AA (ref = 1) (N = 300) 4.82 (2.63-8.85) <0.001 4.27 (2.10-8.70) <0.001
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FIT sensitivity for CRC could not be explained by either
location or age. It can only be speculated on whether the
sex difference is due to other confounders, such as
tumour size, tumour biology (e.g. blood vessel density),
or colon transit time, which is known to be longer in fe-
males [15]. Other authors hypothesized that the higher
serum concentration of haemoglobin in male blood
could cause higher FIT positivity when blood is lost in
the colon [3]. This cannot be confirmed in the current
study, as the serum haemoglobin level of participants
was not determined. For advanced adenomas, no signifi-
cant difference in sensitivity was found between the
sexes, but males consistently had a higher sensitivity. In
multivariate analysis and stratified 2×2 contingency ta-
bles, it was found that the number and size of lesions
are predictive for test sensitivity. This last observation is
in line with another study that showed that the number
and size of polyps influence test accuracy for detection
of advanced adenomas [16].
Currently, CRC screening with preselection by means
of FIT sampling is a one size fits all approach. Sex spe-
cific screening guidelines could be considered, in order
to optimize the effectiveness of a screening programme
in both males and females [3,17]. Based on the current
results, the lower sensitivity of FIT in women could lead
to a smaller benefit from screening for females. How-
ever, the lower sensitivity of FIT in females may be
counterbalanced by a higher participation rate, as was
found in the English and Scottish screening programmes
[18,19]. Therefore, multiple factors need to be taken into
account determine the efficiency of a CRC screening
programme. When preferred, the same sensitivity for
CRC could be easily reached by lowering the cut-off
value in females. In the absence of a sex difference in the
sensitivity for advanced adenomas, sex specific cut-off
values in screening seem unnecessary, as prevalent cancers
will presumably be detected in the first screening rounds.
In the next screening rounds the focus of screening may
shift to detection of advanced adenomas. In addition, indi-
vidualising screening guidelines adds to the complexity of
a screening programme and should only be adopted if the
expected benefits are substantial. Individualized screening
guidelines may confuse providers and consumers to the
point of decreasing adherence [20].
The current study provides insight into the relation be-
tween sex and the test characteristics of FIT for detection
of CRC and advanced adenomas. To the best of our know-
ledge, this is the first study to observe that sex specific dif-
ferences in FIT sensitivity are mainly present in CRC and
only small in advanced adenomas. Each participant in the
study underwent complete colonoscopy regardless of FIT
outcome. This enabled direct calculation of not only sensi-
tivity but specificity as well. The high number of advancedcolonic neoplasia in the referral population that was used,
enabled us to stratify for CRC, which was not possible be-
fore [3].
For proper interpretation of the results, some limita-
tions need to be discussed. The main limitation is that a
heterogeneous population was studied. That is, both
symptomatic subjects and subjects with higher than
average risk for CRC (e.g. derived from adenoma and
CRC surveillance programmes) were included. Conse-
quently, it cannot be ruled out that, even after exclusion
of subjects with anaemia and haematochezia, sensitivity
may be overestimated and specificity underestimated
due to work-up bias [21]. This may occur as symptom-
atic participants have an increased likelihood for having
both a positive FIT and an advanced colorectal neo-
plasm. This is why the current study for instance did not
aim to provide an optimal cut-off value for each sex in
the screening setting. On the other hand, using non-
screening study populations to investigate test character-
istics in subgroups that are usually underrepresented in
screening studies seems justified. This is supported by a
previous study that showed that CRC cases from a non
screening setting had similar results as CRC cases from
a screening study [22]. Another limitation it that location
of lesions was assessed by the endoscopists by recogni-
tion of colonic landmarks. Although this is the most
commonly used method for assessment of the location,
the accuracy with which the location of the neoplastic
lesions can be determined may not be optimal. In
addition, as size of CRC was not prospectively scored, it
was not possible to use this variable in the logistic re-
gression analysis. Finally, there may be other explanatory
variables for FIT performance that were not included,
like for instance the use of NSAIDs [9].
Conclusions
In conclusion, males were found to have a higher FIT
sensitivity and a lower specificity for CRC compared to
females. However, as the shapes of and the areas under
the ROC curves are similar, equal characteristics can be
achieved by allowing different cut-off values for both
sexes. Location of CRC and age of the individuals are not
responsible for the observed differences in sensitivity.
Whether the difference is relevant in screening remains
questionable. No significant difference in test characteris-
tics for advanced adenomas was found between the sexes.
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